Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 2/2011

01-04-2011

The Pathogenesis of Systemic Sclerosis Revisited

Authors: Matthias Geyer, Ulf Müller-Ladner

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2011

Login to get access

Abstract

Although infectiological stimuli, environmental factors and genotypic features are known to contribute to the initiation and perpetuation of systemic sclerosis (SSc), its etiology still remains to be enigmatic, and less elusive insights are to be achieved by ongoing and future investigations. Being characterized, however, as chronic autoimmune disease with excessive collagen accumulation in skin, synovia and visceral organs such as lung, heart, and digestive tract along with obliterating angiopathy, the pathophysiology of SSc can be summarized as being based on imbalances of the cellular and humoral immune system, vascular dysfunction and activation of resident connective tissue cells. A complex interplay between these major components manages to establish and maintain the inability of the vasculature to adequately react to the need for dilatation, constriction and growth of new vessels, to cause the increased deposition of extracellular matrix constituents as well as to facilitate immunological disarrangement. Despite parallels to the chicken and egg causality dilemma, all of these account for what later clinicians observe in patients suffering from Raynaud’s phenomenon, digital ulcers, sclerodactyly, rigidity of the face, microstomia, sicca syndrome, dyspnea, dry cough, pulmonary hypertension, palpitations, syncopes, renal insufficiency, dysphagia, gastroesophageal reflux, dyspepsia, generalized arthralgias, but also dyspareunia, or erectile dysfunction.
Literature
1.
go back to reference Lunardi C, Dolcino M, Peterlana D et al (2006) Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 3:e2PubMedCrossRef Lunardi C, Dolcino M, Peterlana D et al (2006) Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med 3:e2PubMedCrossRef
2.
go back to reference Kahan A, Menkes CJ, Amor B (1986) Defective Epstein–Barr virus specific suppressor T cell function in progressive systemic sclerosis. Ann Rheum Dis 45:553–560PubMedCrossRef Kahan A, Menkes CJ, Amor B (1986) Defective Epstein–Barr virus specific suppressor T cell function in progressive systemic sclerosis. Ann Rheum Dis 45:553–560PubMedCrossRef
3.
go back to reference Zakrzewska K, Corcioli F, Carlsen KM et al (2009) Human parvovirus B19 (B19V) infection in systemic sclerosis patients. Intervirology 52:279–282PubMedCrossRef Zakrzewska K, Corcioli F, Carlsen KM et al (2009) Human parvovirus B19 (B19V) infection in systemic sclerosis patients. Intervirology 52:279–282PubMedCrossRef
4.
go back to reference Ohtsuka T, Yamazaki S (2004) Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin. Br J Dermatol 150:1091–1095PubMedCrossRef Ohtsuka T, Yamazaki S (2004) Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin. Br J Dermatol 150:1091–1095PubMedCrossRef
5.
go back to reference Fox RI, Kang HI (1992) Genetic and environmental factors in systemic sclerosis. Curr Opin Rheumatol 4:857–861PubMed Fox RI, Kang HI (1992) Genetic and environmental factors in systemic sclerosis. Curr Opin Rheumatol 4:857–861PubMed
6.
go back to reference Rustin MH, Bull HA, Ziegler V et al (1990) Silica-associated systemic sclerosis is clinically, serologically and immunologically indistinguishable from idiopathic systemic sclerosis. Br J Dermatol 123:725–734PubMedCrossRef Rustin MH, Bull HA, Ziegler V et al (1990) Silica-associated systemic sclerosis is clinically, serologically and immunologically indistinguishable from idiopathic systemic sclerosis. Br J Dermatol 123:725–734PubMedCrossRef
7.
go back to reference Calvani N, Silvestris F, Dammacco F (2001) Familial systemic sclerosis following exposure to organic solvents and the possible implication of genetic factors. Ann Ital Med Int 16:175–178PubMed Calvani N, Silvestris F, Dammacco F (2001) Familial systemic sclerosis following exposure to organic solvents and the possible implication of genetic factors. Ann Ital Med Int 16:175–178PubMed
8.
go back to reference Garcia-Zamalloa AM, Ojeda E, Gonzalez-Beneitez C, Goni J, Garrido A (1994) Systemic sclerosis and organic solvents: early diagnosis in industry. Ann Rheum Dis 53:618PubMedCrossRef Garcia-Zamalloa AM, Ojeda E, Gonzalez-Beneitez C, Goni J, Garrido A (1994) Systemic sclerosis and organic solvents: early diagnosis in industry. Ann Rheum Dis 53:618PubMedCrossRef
9.
go back to reference Allanore Y, Wipff J, Kahan A, Boileau C (2007) Genetic basis for systemic sclerosis. Joint Bone Spine 74:577–583PubMedCrossRef Allanore Y, Wipff J, Kahan A, Boileau C (2007) Genetic basis for systemic sclerosis. Joint Bone Spine 74:577–583PubMedCrossRef
10.
go back to reference Dieude P, Guedj M, Wipff J et al (2009) STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 60:2472–2479PubMedCrossRef Dieude P, Guedj M, Wipff J et al (2009) STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 60:2472–2479PubMedCrossRef
11.
go back to reference Tan FK, Arnett FC (2000) Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol 12:511–519PubMedCrossRef Tan FK, Arnett FC (2000) Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol 12:511–519PubMedCrossRef
12.
go back to reference Fantonetti G (1838) Case of general induration of the skin. Dublin J Med Sci 13:158–159 Fantonetti G (1838) Case of general induration of the skin. Dublin J Med Sci 13:158–159
13.
go back to reference Goetz RH (1945) The pathology of progressive systemic sclerosis (generalised scleroderma) with special reference to changes in the viscera. Clin Proc J Cape Town Postgrad Med Ass 4:337–341 Goetz RH (1945) The pathology of progressive systemic sclerosis (generalised scleroderma) with special reference to changes in the viscera. Clin Proc J Cape Town Postgrad Med Ass 4:337–341
14.
go back to reference LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
15.
go back to reference Kahaleh MB (2004) Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 16:718–722PubMedCrossRef Kahaleh MB (2004) Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 16:718–722PubMedCrossRef
16.
go back to reference Scheja A, Akesson A, Geborek P et al (2001) Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 3:178–182PubMedCrossRef Scheja A, Akesson A, Geborek P et al (2001) Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Res 3:178–182PubMedCrossRef
17.
go back to reference Matucci-Cerinic M, Pietrini U, Marabini S (1990) Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. Clin Exp Rheumatol 8:561–565PubMed Matucci-Cerinic M, Pietrini U, Marabini S (1990) Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. Clin Exp Rheumatol 8:561–565PubMed
18.
go back to reference Cerinic MM, Valentini G, Sorano GG et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285–295PubMedCrossRef Cerinic MM, Valentini G, Sorano GG et al (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32:285–295PubMedCrossRef
19.
go back to reference McHugh NJ, Distler O, Giacomelli R, Riemekasten G (2003) Non organ based laboratory markers in systemic sclerosis. Clin Exp Rheumatol 21:S32–S38PubMed McHugh NJ, Distler O, Giacomelli R, Riemekasten G (2003) Non organ based laboratory markers in systemic sclerosis. Clin Exp Rheumatol 21:S32–S38PubMed
20.
go back to reference Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785–792PubMedCrossRef Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98:785–792PubMedCrossRef
21.
go back to reference Cambrey AD, Harrison NK, Dawes KE et al (1994) Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 11:439–445PubMed Cambrey AD, Harrison NK, Dawes KE et al (1994) Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 11:439–445PubMed
22.
go back to reference Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557–567PubMedCrossRef Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557–567PubMedCrossRef
23.
go back to reference Humbert M, Morrell NW, Archer SL et al (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S–24SPubMedCrossRef Humbert M, Morrell NW, Archer SL et al (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S–24SPubMedCrossRef
24.
25.
go back to reference Park JH, Sung YK, Bae SC, Song SY, Seo HS, Jun JB (2009) Ulnar artery vasculopathy in systemic sclerosis. Rheumatol Int 29:1081–1086PubMedCrossRef Park JH, Sung YK, Bae SC, Song SY, Seo HS, Jun JB (2009) Ulnar artery vasculopathy in systemic sclerosis. Rheumatol Int 29:1081–1086PubMedCrossRef
26.
go back to reference Cool CD, Stewart JS, Werahera P et al (1999) Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155:411–419PubMedCrossRef Cool CD, Stewart JS, Werahera P et al (1999) Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155:411–419PubMedCrossRef
27.
go back to reference Rhew EY, Barr WG (2004) Scleroderma renal crisis: new insights and developments. Curr Rheumatol Rep 6:129–136PubMedCrossRef Rhew EY, Barr WG (2004) Scleroderma renal crisis: new insights and developments. Curr Rheumatol Rep 6:129–136PubMedCrossRef
28.
go back to reference Distler O, Distler JH, Scheid A et al (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95:109–116PubMedCrossRef Distler O, Distler JH, Scheid A et al (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95:109–116PubMedCrossRef
29.
go back to reference Koch AE, Distler O (2007) Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S3PubMedCrossRef Koch AE, Distler O (2007) Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S3PubMedCrossRef
30.
go back to reference Müller-Ladner U, Distler O, Ibba-Manneschi L, Neumann E, Gay S (2009) Mechanisms of vascular damage in systemic sclerosis. Autoimmunity 42:587–595CrossRef Müller-Ladner U, Distler O, Ibba-Manneschi L, Neumann E, Gay S (2009) Mechanisms of vascular damage in systemic sclerosis. Autoimmunity 42:587–595CrossRef
31.
go back to reference Del Papa N, Quirici N, Soligo D et al (2006) Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54:2605–2615PubMedCrossRef Del Papa N, Quirici N, Soligo D et al (2006) Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54:2605–2615PubMedCrossRef
32.
go back to reference Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364:603–610PubMedCrossRef Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364:603–610PubMedCrossRef
33.
go back to reference Avouac J, Juin F, Wipff J et al (2008) Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis 67:1455–1460PubMedCrossRef Avouac J, Juin F, Wipff J et al (2008) Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis 67:1455–1460PubMedCrossRef
34.
go back to reference Distler JH, Allanore Y, Avouac J et al (2009) EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis 68:163–168PubMedCrossRef Distler JH, Allanore Y, Avouac J et al (2009) EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis 68:163–168PubMedCrossRef
35.
go back to reference Cipriani P, Guiducci S, Miniati I et al (2007) Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56:1994–2004PubMedCrossRef Cipriani P, Guiducci S, Miniati I et al (2007) Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 56:1994–2004PubMedCrossRef
36.
go back to reference D'Alessio S, Fibbi G, Cinelli M et al (2004) Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 50:3275–3285PubMedCrossRef D'Alessio S, Fibbi G, Cinelli M et al (2004) Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 50:3275–3285PubMedCrossRef
37.
go back to reference Suri C, Jones PF, Patan S et al (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171–1180PubMedCrossRef Suri C, Jones PF, Patan S et al (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171–1180PubMedCrossRef
38.
go back to reference Eklund L, Olsen BR (2006) Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 312:630–641PubMedCrossRef Eklund L, Olsen BR (2006) Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 312:630–641PubMedCrossRef
39.
go back to reference Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43:889–893PubMedCrossRef Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43:889–893PubMedCrossRef
40.
go back to reference Distler O, Del Rosso A, Giacomelli R et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4:R11PubMedCrossRef Distler O, Del Rosso A, Giacomelli R et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4:R11PubMedCrossRef
41.
go back to reference Yamagishi S, Imaizumi T (2005) Pericyte biology and diseases. Int J Tissue React 27:125–135PubMed Yamagishi S, Imaizumi T (2005) Pericyte biology and diseases. Int J Tissue React 27:125–135PubMed
42.
go back to reference Helmbold P, Fiedler E, Fischer M, Marsch W (2004) Hyperplasia of dermal microvascular pericytes in scleroderma. J Cutan Pathol 31:431–440PubMedCrossRef Helmbold P, Fiedler E, Fischer M, Marsch W (2004) Hyperplasia of dermal microvascular pericytes in scleroderma. J Cutan Pathol 31:431–440PubMedCrossRef
43.
go back to reference Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM (1999) Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 42:930–941PubMedCrossRef Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM (1999) Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 42:930–941PubMedCrossRef
44.
go back to reference Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ (2005) Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7:R1113–R1123PubMedCrossRef Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ (2005) Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7:R1113–R1123PubMedCrossRef
45.
go back to reference Lin SL, Kisseleva T, Brenner DA, Duffield JS (2008) Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173:1617–1627PubMedCrossRef Lin SL, Kisseleva T, Brenner DA, Duffield JS (2008) Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173:1617–1627PubMedCrossRef
46.
go back to reference Abraham DJ, Varga J (2005) Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26:587–595PubMedCrossRef Abraham DJ, Varga J (2005) Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26:587–595PubMedCrossRef
47.
go back to reference Whitfield ML, Finlay DR, Murray JI et al (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100:12319–12324PubMedCrossRef Whitfield ML, Finlay DR, Murray JI et al (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100:12319–12324PubMedCrossRef
48.
go back to reference Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165:6635–6643PubMed Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165:6635–6643PubMed
49.
go back to reference Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918–1927PubMedCrossRef Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918–1927PubMedCrossRef
50.
go back to reference Hasegawa M, Hamaguchi Y, Yanaba K et al (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954–966PubMedCrossRef Hasegawa M, Hamaguchi Y, Yanaba K et al (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954–966PubMedCrossRef
51.
go back to reference Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778–784PubMedCrossRef Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778–784PubMedCrossRef
52.
go back to reference Rosenbaum J, Pottinger BE, Woo P et al (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72:450–456PubMed Rosenbaum J, Pottinger BE, Woo P et al (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72:450–456PubMed
53.
go back to reference Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97:111–119PubMedCrossRef Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97:111–119PubMedCrossRef
54.
go back to reference Baroni SS, Santillo M, Bevilacqua F et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667–2676PubMedCrossRef Baroni SS, Santillo M, Bevilacqua F et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667–2676PubMedCrossRef
55.
go back to reference Hasegawa M, Fujimoto M, Takehara K, Sato S (2005) Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 39:1–7PubMedCrossRef Hasegawa M, Fujimoto M, Takehara K, Sato S (2005) Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 39:1–7PubMedCrossRef
56.
go back to reference Stummvoll GH, Aringer M, Grisar J et al (2004) Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis 63:569–574PubMedCrossRef Stummvoll GH, Aringer M, Grisar J et al (2004) Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis 63:569–574PubMedCrossRef
57.
go back to reference Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649–3659PubMed Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649–3659PubMed
59.
go back to reference Steen VD, Engel EE, Charley MR, Medsger TA Jr (1996) Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J Rheumatol 23:646–649PubMed Steen VD, Engel EE, Charley MR, Medsger TA Jr (1996) Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J Rheumatol 23:646–649PubMed
60.
go back to reference French LE, Lessin SR, Addya K et al (2001) Identification of clonal T cells in the blood of patients with systemic sclerosis: positive correlation with response to photopheresis. Arch Dermatol 137:1309–1313PubMed French LE, Lessin SR, Addya K et al (2001) Identification of clonal T cells in the blood of patients with systemic sclerosis: positive correlation with response to photopheresis. Arch Dermatol 137:1309–1313PubMed
61.
62.
go back to reference Wangoo A, Sparer T, Brown IN et al (2001) Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 166:3432–3439PubMed Wangoo A, Sparer T, Brown IN et al (2001) Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 166:3432–3439PubMed
63.
go back to reference Lakos G, Melichian D, Wu M, Varga J (2006) Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 73:224–237PubMedCrossRef Lakos G, Melichian D, Wu M, Varga J (2006) Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 73:224–237PubMedCrossRef
64.
go back to reference Tan FK, Zhou X, Mayes MD et al (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45:694–702CrossRef Tan FK, Zhou X, Mayes MD et al (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45:694–702CrossRef
65.
go back to reference Mavalia C, Scaletti C, Romagnani P et al (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751–1758PubMed Mavalia C, Scaletti C, Romagnani P et al (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751–1758PubMed
66.
go back to reference Atamas SP, Yurovsky VV, Wise R et al (1999) Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42:1168–1178PubMedCrossRef Atamas SP, Yurovsky VV, Wise R et al (1999) Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42:1168–1178PubMedCrossRef
67.
go back to reference Rottoli P, Magi B, Perari MG et al (2005) Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5:1423–1430PubMedCrossRef Rottoli P, Magi B, Perari MG et al (2005) Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5:1423–1430PubMedCrossRef
68.
go back to reference Chizzolini C, Parel Y, De Luca C et al (2003) Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 48:2593–2604PubMedCrossRef Chizzolini C, Parel Y, De Luca C et al (2003) Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 48:2593–2604PubMedCrossRef
69.
go back to reference Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275–284PubMed Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275–284PubMed
70.
go back to reference Giacomelli R, Cipriani P, Fulminis A et al (2001) Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 125:310–315PubMedCrossRef Giacomelli R, Cipriani P, Fulminis A et al (2001) Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 125:310–315PubMedCrossRef
71.
go back to reference Giacomelli R, Matucci-Cerinic M, Cipriani P et al (1998) Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 41:327–334PubMedCrossRef Giacomelli R, Matucci-Cerinic M, Cipriani P et al (1998) Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 41:327–334PubMedCrossRef
72.
go back to reference Chang HY, Chi JT, Dudoit S et al (2002) Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 99:12877–12882PubMedCrossRef Chang HY, Chi JT, Dudoit S et al (2002) Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 99:12877–12882PubMedCrossRef
73.
go back to reference Abraham DJ, Eckes B, Rajkumar V, Krieg T (2007) New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 9:136–143PubMedCrossRef Abraham DJ, Eckes B, Rajkumar V, Krieg T (2007) New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 9:136–143PubMedCrossRef
74.
go back to reference Desmouliere A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7–12PubMedCrossRef Desmouliere A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7–12PubMedCrossRef
75.
go back to reference Kalluri R, Neilson EG (2003) Epithelial–mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784PubMed Kalluri R, Neilson EG (2003) Epithelial–mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784PubMed
76.
go back to reference Zeisberg M, Hanai J, Sugimoto H et al (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964–968PubMedCrossRef Zeisberg M, Hanai J, Sugimoto H et al (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964–968PubMedCrossRef
77.
go back to reference Abe R, Donnelly SC, Peng T, Bucala R, Metz CN (2001) Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166:7556–7562PubMed Abe R, Donnelly SC, Peng T, Bucala R, Metz CN (2001) Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166:7556–7562PubMed
78.
go back to reference Cipriani P, Franca Milia A, Liakouli V et al (2006) Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheum 54:3022–3033PubMedCrossRef Cipriani P, Franca Milia A, Liakouli V et al (2006) Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheum 54:3022–3033PubMedCrossRef
79.
go back to reference Phillips RJ, Burdick MD, Hong K et al (2004) Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114:438–446PubMed Phillips RJ, Burdick MD, Hong K et al (2004) Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114:438–446PubMed
80.
go back to reference Kuwana M, Okazaki Y, Kodama H et al (2003) Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 74:833–845PubMedCrossRef Kuwana M, Okazaki Y, Kodama H et al (2003) Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 74:833–845PubMedCrossRef
81.
go back to reference Pannu J, Trojanowska M (2004) Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 16:739–745PubMedCrossRef Pannu J, Trojanowska M (2004) Recent advances in fibroblast signaling and biology in scleroderma. Curr Opin Rheumatol 16:739–745PubMedCrossRef
83.
go back to reference Varga J, Bashey RI (1995) Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 12:187–199PubMedCrossRef Varga J, Bashey RI (1995) Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 12:187–199PubMedCrossRef
84.
go back to reference Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358PubMedCrossRef Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358PubMedCrossRef
86.
go back to reference Daniels CE, Wilkes MC, Edens M et al (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308–1316PubMed Daniels CE, Wilkes MC, Edens M et al (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308–1316PubMed
87.
go back to reference Chen SJ, Ning H, Ishida W et al (2006) The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 281:21183–21197PubMedCrossRef Chen SJ, Ning H, Ishida W et al (2006) The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 281:21183–21197PubMedCrossRef
88.
go back to reference Igarashi A, Nashiro K, Kikuchi K et al (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 106:729–733PubMedCrossRef Igarashi A, Nashiro K, Kikuchi K et al (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 106:729–733PubMedCrossRef
89.
go back to reference Leask A (2009) Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma. Front Biosci (Elite Ed) 1:115–122 Leask A (2009) Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma. Front Biosci (Elite Ed) 1:115–122
90.
go back to reference Gay S, Jones RE Jr, Huang GQ, Gay RE (1989) Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 92:301–303PubMedCrossRef Gay S, Jones RE Jr, Huang GQ, Gay RE (1989) Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 92:301–303PubMedCrossRef
91.
go back to reference Ludwicka A, Ohba T, Trojanowska M et al (1995) Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22:1876–1883PubMed Ludwicka A, Ohba T, Trojanowska M et al (1995) Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22:1876–1883PubMed
92.
go back to reference Jinnin M, Ihn H, Yamane K, Tamaki K (2004) Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 279:41783–41791PubMedCrossRef Jinnin M, Ihn H, Yamane K, Tamaki K (2004) Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 279:41783–41791PubMedCrossRef
93.
go back to reference Kaviratne M, Hesse M, Leusink M et al (2004) IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 173:4020–4029PubMed Kaviratne M, Hesse M, Leusink M et al (2004) IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 173:4020–4029PubMed
94.
go back to reference Postlethwaite AE, Holness MA, Katai H, Raghow R (1992) Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 90:1479–1485PubMedCrossRef Postlethwaite AE, Holness MA, Katai H, Raghow R (1992) Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 90:1479–1485PubMedCrossRef
95.
go back to reference Salmon-Ehr V, Serpier H, Nawrocki B et al (1996) Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 132:802–806PubMedCrossRef Salmon-Ehr V, Serpier H, Nawrocki B et al (1996) Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 132:802–806PubMedCrossRef
96.
go back to reference Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328–332PubMed Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328–332PubMed
97.
go back to reference Tsuji-Yamada J, Nakazawa M, Minami M, Sasaki T (2001) Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 28:1252–1258PubMed Tsuji-Yamada J, Nakazawa M, Minami M, Sasaki T (2001) Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 28:1252–1258PubMed
98.
go back to reference Distler JH, Jungel A, Caretto D et al (2006) Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 54:214–225PubMedCrossRef Distler JH, Jungel A, Caretto D et al (2006) Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 54:214–225PubMedCrossRef
99.
go back to reference Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S (2005) Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 52:2889–2896PubMedCrossRef Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S (2005) Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 52:2889–2896PubMedCrossRef
100.
go back to reference Jimenez SA, Freundlich B, Rosenbloom J (1984) Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 74:1112–1116PubMedCrossRef Jimenez SA, Freundlich B, Rosenbloom J (1984) Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 74:1112–1116PubMedCrossRef
101.
go back to reference Ghosh AK, Yuan W, Mori Y, Chen S, Varga J (2001) Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 276:11041–11048PubMedCrossRef Ghosh AK, Yuan W, Mori Y, Chen S, Varga J (2001) Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 276:11041–11048PubMedCrossRef
102.
go back to reference Arai T, Abe K, Matsuoka H et al (2000) Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol 278:L914–L922PubMed Arai T, Abe K, Matsuoka H et al (2000) Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol 278:L914–L922PubMed
103.
go back to reference Barbarin V, Xing Z, Delos M, Lison D, Huaux F (2005) Pulmonary overexpression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol 288:L841–L848PubMedCrossRef Barbarin V, Xing Z, Delos M, Lison D, Huaux F (2005) Pulmonary overexpression of IL-10 augments lung fibrosis and Th2 responses induced by silica particles. Am J Physiol Lung Cell Mol Physiol 288:L841–L848PubMedCrossRef
104.
go back to reference Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J (1999) Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol 112:49–57PubMedCrossRef Chen SJ, Yuan W, Mori Y, Levenson A, Trojanowska M, Varga J (1999) Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol 112:49–57PubMedCrossRef
105.
go back to reference Chen SJ, Artlett CM, Jimenez SA, Varga J (1998) Modulation of human alpha1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro. Gene 215:101–110PubMedCrossRef Chen SJ, Artlett CM, Jimenez SA, Varga J (1998) Modulation of human alpha1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro. Gene 215:101–110PubMedCrossRef
106.
go back to reference Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M (2002) Ets1 is an effector of the transforming growth factor beta (TGF-beta ) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J Biol Chem 277:20399–20408PubMedCrossRef Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M (2002) Ets1 is an effector of the transforming growth factor beta (TGF-beta ) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J Biol Chem 277:20399–20408PubMedCrossRef
107.
go back to reference Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M (2001) Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 276:20839–20848PubMedCrossRef Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M (2001) Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 276:20839–20848PubMedCrossRef
108.
go back to reference Ghosh AK, Bhattacharyya S, Varga J (2004) The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem 279:47455–47463PubMedCrossRef Ghosh AK, Bhattacharyya S, Varga J (2004) The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem 279:47455–47463PubMedCrossRef
109.
go back to reference Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J (2004) Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50:1305–1318PubMedCrossRef Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J (2004) Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 50:1305–1318PubMedCrossRef
Metadata
Title
The Pathogenesis of Systemic Sclerosis Revisited
Authors
Matthias Geyer
Ulf Müller-Ladner
Publication date
01-04-2011
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2/2011
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8193-3

Other articles of this Issue 2/2011

Clinical Reviews in Allergy & Immunology 2/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.